Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. Adagrasib is an inhibitor of G12C mutated KRAS GTPase. It is taken by mouth. It is being developed by Mirati Therapeutics.
via Wikipedia infobox
{{Infobox drug | image = Adagrasib structure.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Krazati | Drugs.com = | MedlinePlus = a623003 | DailyMedID = Adagrasib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = XX77 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).